Authors: Adamson, PC Widemann, BC Reaman, GH Seibel, NL Murphy, RF Gillespie, AF Balis, FM

Citation: Pc. Adamson et al., A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: A Joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group Study, CLIN CANC R, 7(10), 2001, pp. 3034-3039

Authors: Lowe, ES Kitchen, BJ Erdmann, G Stork, LC Bostrom, BC Hutchinson, R Holcenberg, J Reaman, GH Woods, W Franklin, J Widemann, BC Balis, FM Murphy, RF Adamson, PC

Citation: Es. Lowe et al., Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguaninein children with acute lymphoblastic leukemia: a collaborative pediatric oncology branch, NCI, and Children's Cancer Group study, CANC CHEMOT, 47(3), 2001, pp. 199-205

Authors: Widemann, BC Sung, E Anderson, L Salzer, WL Balis, FM Monitjo, KS McCully, C Hawkins, M Adamson, PC

Citation: Bc. Widemann et al., Pharmacokinetics and metabolism of the methotrexate metabolite 2,4-diamino-N-10-methylpteroic acid, J PHARM EXP, 294(3), 2000, pp. 894-901

Authors: Widemann, BC Balis, FM Godwin, KS McCully, C Adamson, PC

Citation: Bc. Widemann et al., The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex (TM)) in a nonhuman primate model, CANC CHEMOT, 44(6), 1999, pp. 439-443

Authors: Widemann, BC Balis, FM Adamson, PC

Citation: Bc. Widemann et al., Dihydrofolate reductase enzyme inhibition assay for plasma methotrexate determination using a 96-well microplate reader, CLIN CHEM, 45(2), 1999, pp. 223-228